Liraglutide and calcitonin

Journal of Diabetes

Volumn 2, Issue 4, 2010, Pages 223-224

  Bloomgarden, Zachary ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; EXENDIN 4; GASTRIN; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE; OMEPRAZOLE; PENTAGASTRIN;

CALCITONIN BLOOD LEVEL; CANCER RISK; DRUG APPROVAL; DRUG INDUCED DISEASE; DRUG LABELING; DRUG MECHANISM; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL; SIDE EFFECT; THYROID HYPERPLASIA; THYROID MEDULLARY CARCINOMA; TREATMENT CONTRAINDICATION;

ANIMALS; CALCITONIN; CARCINOMA; CLINICAL TRIALS AS TOPIC; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MICE; RATS; THYROID NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 78649661323     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/j.1753-0407.2010.00079.x     Document Type: Note

References (12)

1. Victoza Prescribing Information. Available from: (accessed 19 March 2010).
2. Lamari Y, Boissard C, Moukhtar MS, Jullienne A, Rosselin G, Garel JM,. Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagon-like peptide 1. FEBS Lett. 1996; 393: 248-52.
3. Crespel A, De Boisvilliers F, Gros L, Kervran A,. Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line. Endocrinology. 1996; 137: 3674-80.
4. Yamada C, Yamada Y, Tsukiyama K, et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology. 2008; 149: 574-9.
5. Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010; 151: 1473-86.
6. Selawry HP, Becker KL, Bivins LE, Snider RH, Silva OL,. In vitro studies of calcitonin release in man. Horm Metab Res. 1975; 7: 432-7.
7. Erdogan MF, Gursoy A, Kulaksizoglu M,. Long-term effects of elevated gastrin levels on calcitonin secretion. J Endocrinol Invest. 2006; 29: 771-5.
8. Vitale G, Ciccarelli A, Caraglia M, et al. Comparison of two provocative tests for calcitonin in medullary thyroid carcinoma: omeprazole vs pentagastrin. Clin Chem. 2002; 48: 1505-10.
9. Parks M, Rosebraugh C,. Weighing risks and benefits of liraglutide: the FDA's review of a new antidiabetic therapy. N Engl J Med. 2010; 362: 774-7.
10. D'Herbomez M, Caron P, Bauters C, et al. Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking. Eur J Endocrinol. 2007; 157: 749-55.
11. Borget I, De Pouvourville G, Schlumberger M,. Calcitonin determination in patients with nodular thyroid disease. J Clin Endocrinol Metab. 2007; 92: 425-7.
12. Toledo SP, Lourenço DM Jr, Santos MA, Tavares MR, Toledo RA, Correia-Deur JE,. Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics (São Paulo). 2000; 64: 699-706.